BioCentury | May 28, 2020
Finance

argenx parlays myasthenia gravis data into year’s second-largest follow-on at $750M

...€5.90 to €195.90 in Brussels. Targets FCRN (FCGRT) - Neonatal Fc receptor Elizabeth S. Eaton, Staff Writer ARGX-113...
BioCentury | May 27, 2020
Product Development

argenx data put myasthenia gravis therapy a step closer to challenging Soliris, raising year’s second-biggest follow-on

...medical meeting. Targets C5 - Complement 5 FCRN (FCGRT) - Neonatal Fc receptor Sandi Wong, Assistant Editor ARGX-113...
BioCentury | Feb 29, 2020
Product Development

Coming competition in myasthenia gravis

...press releases, JAMA Neurology, Neurology, clinicaltrials.gov Two agents could challenge Soliris: the anti-FCRN mAb efgartigimod (ARGX-113...
...Neonatal Fc receptor MUSK - Muscle associated receptor tyrosine kinase Stephen Hansen, Associate Editor Soliris, eculizumab (5G1.1) ARGX-113...
BioCentury | Feb 8, 2019
Company News

Halozyme grants argenx access to Enhanze subcutaneous delivery tech

...with any product targeting the human neonatal Fc receptor FcRn, including argenx lead compound efgartigimod (ARGX-113...
...Euronext:ARGX; NASDAQ:ARGX), Breda, the Netherlands Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif. Business: Drug delivery Shannon Lehnbeuter ARGX-113...
BioCentury | Jan 24, 2019
Emerging Company Profile

Cabaletta’s CAAR Ts for autoimmunity

...Rituxan rituximab. At least three compounds are in Phase II testing for the indication, including ARGX-113...
BioCentury | Dec 7, 2018
Company News

argenx gets $500M up front from Janssen for CD70 mAb

...also reported detailed data at ASH from a Phase II trial of once-weekly IV efgartigimod (ARGX-113...
...S.E. (Euronext:ARGX; NASDAQ:ARGX), Breda, the Netherlands Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer Sandi Wong ARGX-113...
BioCentury | Dec 4, 2018
Company News

argenx gets $500M up front from Janssen for CD70 mAb

...also reported detailed data at ASH from a Phase II trial of once-weekly IV efgartigimod (ARGX-113...
...neonatal Fc receptor (FCRN; FCGRT) to treat ITP following an end-of-Phase II meeting with FDA. Sandi Wong ARGX-113...
BioCentury | Nov 1, 2018
Clinical News

argenx's CD70 mAb leads to 92% response rate in AML

...reported preliminary data from the trial at last year's ASH meeting (see "argenx Rises on ARGX-113...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...S.E., which plans to present detailed data from its Phase II trial of IV efgartigimod (ARGX-113...
...ISE:AYP) Episalvan Epidermolysis bullosa Interim Ph III EASE data 4Q18 argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) Efgartigimod (ARGX-113...
BioCentury | Sep 28, 2018
Company News

Syntimmune deal helps Alexion diversify beyond Soliris

...FCRN-targeting compounds for an autoimmune disease, according to BioCentury's BCIQ database. The most advanced, efgartigimod (ARGX-113...
Items per page:
1 - 10 of 35